Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
Abstract This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-024-00713-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850101930508943360 |
|---|---|
| author | Linda Cucciniello Eva Blondeaux Claudia Bighin Simona Gasparro Stefania Russo Arianna Dri Palma Pugliese Andrea Fontana Enrico Cortesi Antonella Ferzi Ferdinando Riccardi Valentina Sini Luca Boni Alessandra Fabi Filippo Montemurro Michelino De Laurentiis Grazia Arpino Lucia Del Mastro Lorenzo Gerratana Fabio Puglisi |
| author_facet | Linda Cucciniello Eva Blondeaux Claudia Bighin Simona Gasparro Stefania Russo Arianna Dri Palma Pugliese Andrea Fontana Enrico Cortesi Antonella Ferzi Ferdinando Riccardi Valentina Sini Luca Boni Alessandra Fabi Filippo Montemurro Michelino De Laurentiis Grazia Arpino Lucia Del Mastro Lorenzo Gerratana Fabio Puglisi |
| author_sort | Linda Cucciniello |
| collection | DOAJ |
| description | Abstract This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis. Eighty patients experienced a rCR to first-line anti-HER2 therapy with a TTD > 3 months and HER2 Immunohistochemistry score 3+, presence of non-visceral metastases and 1 metastatic site were significantly associated with higher odds of obtaining a CR. Of the 80 patients achieving a rCR, 56 experienced a CR with a TTD > 18 months, with anti-HER2 therapy being the only variable significantly associated with a higher probability of achieving such sustained CR. |
| format | Article |
| id | doaj-art-2012db973d71471cbb02ae627ee2e863 |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-2012db973d71471cbb02ae627ee2e8632025-08-20T02:39:52ZengNature Portfolionpj Breast Cancer2374-46772024-12-011011910.1038/s41523-024-00713-8Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello0Eva Blondeaux1Claudia Bighin2Simona Gasparro3Stefania Russo4Arianna Dri5Palma Pugliese6Andrea Fontana7Enrico Cortesi8Antonella Ferzi9Ferdinando Riccardi10Valentina Sini11Luca Boni12Alessandra Fabi13Filippo Montemurro14Michelino De Laurentiis15Grazia Arpino16Lucia Del Mastro17Lorenzo Gerratana18Fabio Puglisi19Department of Medicine, University of UdineU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San MartinoDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of GenovaMedical Oncology 1, IRCSS Regina Elena National Cancer InstituteDepartment of Oncology, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC)Department of Medicine, University of UdineUnit of Oncology, Department of Medical, ASST LarianaUnit of Oncology 2, Department of Medical and Oncological Area, Pisa University HospitalDepartment of Radiology, Pathology and Oncology, La Sapienza UniversityMedical Oncology, ASST Ovest Milanese, Ospedale di LegnanoOncology Unit, Antonio Cardarelli HospitalU.O. Centro Oncologico S. Spirito-Nuovo Regina Margherita, ASL Roma 1U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San MartinoMedical Oncology 1, IRCSS Regina Elena National Cancer InstituteGynecological Oncology Unit, Candiolo Cancer Institute, FPO-IRCCSBreast Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Via Mariano Semmola 53Department of Clinical Medicine and Surgery, University of Naples Federico IIDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of GenovaDepartment of Medicine, University of UdineDepartment of Medicine, University of UdineAbstract This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis. Eighty patients experienced a rCR to first-line anti-HER2 therapy with a TTD > 3 months and HER2 Immunohistochemistry score 3+, presence of non-visceral metastases and 1 metastatic site were significantly associated with higher odds of obtaining a CR. Of the 80 patients achieving a rCR, 56 experienced a CR with a TTD > 18 months, with anti-HER2 therapy being the only variable significantly associated with a higher probability of achieving such sustained CR.https://doi.org/10.1038/s41523-024-00713-8 |
| spellingShingle | Linda Cucciniello Eva Blondeaux Claudia Bighin Simona Gasparro Stefania Russo Arianna Dri Palma Pugliese Andrea Fontana Enrico Cortesi Antonella Ferzi Ferdinando Riccardi Valentina Sini Luca Boni Alessandra Fabi Filippo Montemurro Michelino De Laurentiis Grazia Arpino Lucia Del Mastro Lorenzo Gerratana Fabio Puglisi Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer npj Breast Cancer |
| title | Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer |
| title_full | Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer |
| title_fullStr | Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer |
| title_full_unstemmed | Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer |
| title_short | Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer |
| title_sort | clinico pathological predictors of radiologic complete response to first line anti her2 therapy in metastatic breast cancer |
| url | https://doi.org/10.1038/s41523-024-00713-8 |
| work_keys_str_mv | AT lindacucciniello clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT evablondeaux clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT claudiabighin clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT simonagasparro clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT stefaniarusso clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT ariannadri clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT palmapugliese clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT andreafontana clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT enricocortesi clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT antonellaferzi clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT ferdinandoriccardi clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT valentinasini clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT lucaboni clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT alessandrafabi clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT filippomontemurro clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT michelinodelaurentiis clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT graziaarpino clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT luciadelmastro clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT lorenzogerratana clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer AT fabiopuglisi clinicopathologicalpredictorsofradiologiccompleteresponsetofirstlineantiher2therapyinmetastaticbreastcancer |